ElsaLys Biotech Announces Submission of Biologics License Application to FDA for LEUKOTAC® (Inolimomab) for the Treatment of Graft-versus-Host Disease in Adult Patients

ElsaLys Biotech announced the FDA agreement to start the LEUKOTAC® submission process for a Biologics License Application for the treatment of steroid-refractory acute graft-versus-host disease, grade II-IV adult patients.
[ElsaLys Biotech SA]
Press Release

Continue reading “ElsaLys Biotech Announces Submission of Biologics License Application to FDA for LEUKOTAC® (Inolimomab) for the Treatment of Graft-versus-Host Disease in Adult Patients”

Bookmark

No account yet? Register

0
Share

CTLA4Ig-Primed Donor Lymphocyte Infusions Following Haploidentical Transplantation Improve Outcome with a Distinct Pattern of Early Immune Reconstitution as Compared to Conventional Donor Lymphocyte Infusions in Advanced Hematological Malignancies

Investigators explored the efficacy of prophylactic DLI following CTLA4Ig, compared to conventional DLI, in patients with advanced hematological malignancies receiving PTCy-based haploidentical transplantation.
[Bone Marrow Transplantation]
Abstract

Continue reading “CTLA4Ig-Primed Donor Lymphocyte Infusions Following Haploidentical Transplantation Improve Outcome with a Distinct Pattern of Early Immune Reconstitution as Compared to Conventional Donor Lymphocyte Infusions in Advanced Hematological Malignancies”

Bookmark

No account yet? Register

0
Share

GvHD-Free, Relapse-Free Survival Provides Novel Clues for Optimizing Allogeneic-HSCT for Adult T-Cell Leukemia/Lymphoma

The authors performed a nationwide retrospective study of graft-versus-host disease (GvHD)-free, relapse-free survival of patients with allogeneic hematopoietic stem cell transplantation (HSCT)-treated adult T-cell leukemia/lymphoma.
[Bone Marrow Transplantation]
Muranushi, H., Shindo, T., Hishizawa, M., Tokunaga, M., Wake, A., Nakano, N., Eto, T., Hidaka, M., Choi, I., Miyamoto, T., Uchida, N., Moriuchi, Y., Miyazaki, Y., Fukuda, T., Ichinohe, T., Atsuta, Y., & Kato, K. (2020). GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma. Bone Marrow Transplantation, 1–12. https://doi.org/10.1038/s41409-020-00996-y Cite
Abstract

Continue reading “GvHD-Free, Relapse-Free Survival Provides Novel Clues for Optimizing Allogeneic-HSCT for Adult T-Cell Leukemia/Lymphoma”

Bookmark

No account yet? Register

0
Share

Effect of Sirolimus Levels between Days 11 and 20 after Allogeneic Stem Cell Transplantation on the Risk of Hepatic Sinusoidal Obstruction Syndrome

Scientists analyzed 260 consecutive patients who underwent allogeneic hematopoietic stem cell transplantation following myeloablative conditioning using total body irradiation-based or chemotherapy only regimens, with sirolimus plus tacrolimus for graft-versus-host disease prophylaxis.
[Bone Marrow Transplantation]
Agrawal, V., Ranganath, P., Ervin, K. D., Schmidt, C. A., Cox, E. A., Nelson, R. P., Schwartz, J. E., Zaid, M. A., Abonour, R., Robertson, M. J., Brinda, B. J., Griffin, S. P., Thakrar, T. C., & Farag, S. S. (2020). Effect of Sirolimus levels between days 11 and 20 after allogeneic stem cell transplantation on the risk of hepatic sinusoidal obstruction syndrome. Bone Marrow Transplantation, 1–8. https://doi.org/10.1038/s41409-020-0987-1 Cite
Abstract

Continue reading “Effect of Sirolimus Levels between Days 11 and 20 after Allogeneic Stem Cell Transplantation on the Risk of Hepatic Sinusoidal Obstruction Syndrome”

Bookmark

No account yet? Register

0
Share

Phase I Dose Escalation Study of Naive T-Cell Depleted Donor Lymphocyte Infusion following Allogeneic Stem Cell Transplantation

In this Phase I dose escalation study, the authors assessed the safety of a donor lymphocyte infusion that was depleted of CD45RA+ naive T cells.
[Bone Marrow Transplantation]
Maung, K. K., Chen, B. J., Barak, I., Li, Z., Rizzieri, D. A., Gasparetto, C., Sullivan, K. M., Long, G. D., Engemann, A. M., Waters-Pick, B., Nichols, K. R., Lopez, R., Kang, Y., Sarantopoulos, S., Sung, A. D., Chao, N. J., & Horwitz, M. E. (2020). Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. Bone Marrow Transplantation, 1–7. https://doi.org/10.1038/s41409-020-0991-5 Cite
Abstract

Continue reading “Phase I Dose Escalation Study of Naive T-Cell Depleted Donor Lymphocyte Infusion following Allogeneic Stem Cell Transplantation”

Bookmark

No account yet? Register

0
Share

Long-Term Outcomes and Risk Factor Analysis of Steroid-Refractory Graft versus Host Disease after Hematopoietic Stem Cell Transplantation

Researchers conducted a retrospective study on outcomes and risk factors associated with acute and chronic steroid-refractory graft versus host disease in a large cohort of 1207 patients receiving hematopoietic stem cell transplantation in Saint Louis Hospital between 2007 and 2017.
[Bone Marrow Transplantation]
Abstract

Continue reading “Long-Term Outcomes and Risk Factor Analysis of Steroid-Refractory Graft versus Host Disease after Hematopoietic Stem Cell Transplantation”

Bookmark

No account yet? Register

0
Share
Share